Lamond David

DirectorQuince Therapeutics, Inc. (QNCX) · full profile →Form 4 · filed Dec 14, 2023
Net Buying
Open-Market Buys
$69K
Open-Market Sells
$0
Net Open-Market Flow
$69K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 14, 2023Buy(P)23K$1.04$24K2.3M
Dec 13, 2023Buy(P)23K$1.00$23K2.3M
Dec 12, 2023Buy(P)300$1.00$3002.3M
Dec 12, 2023Buy(P)22K$1.02$23K2.3M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-058694) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about QNCX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001209191-23-058694"
Ask your agent
Use Arkolith to summarize insider buying and selling at Quince Therapeutics, Inc.
over the last 90 days and cite the filings.